BIGAL MARCELO 4

What Happened

• Marcelo Bigal, a director of Pacira BioSciences (PCRX), received equity awards on June 10, 2026: 6,405 restricted stock units (RSUs) and a derivative award covering 10,891 shares. Both grants show $0 purchase price; total shares covered = 17,296. This is an awards/grant transaction (not a purchase or sale).

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (appears timely).
• Price: $0.00 per share (award/grant).
• Shares covered: 6,405 RSUs (F1) + 10,891 derivative units/options (F2) = 17,296 total.
• Post-transaction holdings: Not specified in the provided filing.
• Footnotes:
  • F1: RSUs vest on June 10, 2027 if the reporting person remains in continuous service; each RSU converts to one share.
  • F2: The stock option vests and becomes exercisable on June 10, 2027, subject to continuous service.
• No indication of a 10b5-1 plan, tax-withholding sale, or late filing flag in the provided data.

Context

• The RSUs are restricted until vesting and the derivative award is an option-like grant that becomes exercisable in one year; no shares were sold or exercised at grant. These awards require continued service to vest and carry no immediate cash cost to the insider.